Antibiotic discovery: Combatting bacterial resistance in cells and in biofilm communities

Molecules

Volumn 20, Issue 4, 2015, Pages 5286-5298

  Penesyan, Anahit ^a   Gillings, Michael ^a   Paulsen, Ian T ^a  

^a MACQUARIE UNIVERSITY   (Australia)

Author keywords

Bacterial evolution; Biofilm matrix; Drug discovery; EDNA; Infection control; Natural products; Opportunistic pathogens; Quorum sensing; Unculturable microorganisms

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIUM; BIOFILM; DRUG DEVELOPMENT; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; TRENDS;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL PHYSIOLOGICAL PHENOMENA; BIOFILMS; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; HUMANS;

EID: 84928810717     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20045286     Document Type: Review

References (89)

1. Singh, S.B.; Barrett, J.F. Empirical antibacterial drug discovery - Foundation in natural products. Biochem. Pharmacol. 2006, 71, 1006-1015.
2. Lerner, P.I. Producing penicillin. N. Engl. J. Med. 2004, 351, 524.
3. Barriere, S.L. Clinical, economic and societal impact of antibiotic resistance. Expert Opin. Pharmacother. 2015, 16, 151-153.
4. Alanis, A.J. Resistance to antibiotics: Are we in the post-antibiotic era? Arch. Med. Res. 2005, 36, 697-705.
5. World Health Organization. Antimicrobial Resistance: Global Report on Surveillance; World Health Organization: Geneva, Switzerland, 2014.
6. Nadell, C.D.; Xavier, J.B.; Foster, K.R. The sociobiology of biofilms. FEMS Microbiol. Rev. 2009, 33, 206-224.
7. Camilli, A.; Bassler, B.L. Bacterial small-molecule signaling pathways. Science 2006, 311, 1113-1116.
8. Flemming, H.C.; Wingender, J. The biofilm matrix. Nat. Rev. Microbiol. 2010, 8, 623-633.
9. Nikaido, H. Multiple antibiotic resistance and efflux. Curr. Opin. Microbiol. 1998, 1, 516-523.
10. Paulsen, I.T. Multidrug efflux pumps and resistance: Regulation and evolution. Curr. Opin. Microbiol. 2003, 6, 446-451.
11. Martinez, J.L.; Coque, T.M.; Baquero, F. What is a resistance gene? Ranking risk in resistomes. Nat. Rev. Microbiol. 2015, 13, 116-123.
12. Perry, J.A.; Wright, G.D. Forces shaping the antibiotic resistome. Bioessays 2014, 36, 1179-1184.
13. D'Costa, V.M.; McGrann, K.M.; Hughes, D.W.; Wright, G.D. Sampling the antibiotic resistome. Science 2006, 311, 374-377.
14. Sommer, M.O.A.; Dantas, G.; Church, G.M. Functional characterization of the antibiotic resistance reservoir in the human microflora. Science 2009, 325, 1128-1131.
15. Wright, G.D. The antibiotic resistome: The nexus of chemical and genetic diversity. Nat. Rev. Microbiol. 2007, 5, 175-186.
16. Wright, G.D. Antibiotic resistance in the environment: A link to the clinic? Curr. Opin. Microbiol. 2010, 13, 589-594.
17. Gillings, M.R. Evolutionary consequences of antibiotic use for the resistome, mobilome, and microbial pangenome. Front. Microbiol. 2013, 4, doi:10.3389/fmicb.2013.00004.
18. Brown, M.G.; Balkwill, D.L. Antibiotic resistance in bacteria isolated from the deep terrestrial subsurface. Microb. Ecol. 2009, 57, 484-493.
19. Miteva, V.I.; Sheridan, P.P.; Brenchley, J.E. Phylogenetic and physiological diversity of microorganisms isolated from a deep greenland glacier ice core. Appl. Environ. Microbiol. 2004, 70, 202-213.
20. D'Costa, V.M.; King, C.E.; Kalan, L.; Morar, M.; Sung, W.W.L.; Schwarz, C.; Froese, D.; Zazula, G.; Calmels, F.; Debruyne, R.; et al. Antibiotic resistance is ancient. Nature 2011, 477, 457-461.
21. Paulsen, I.T.; Brown, M.H.; Skurray, R.A. Proton-dependent multidrug efflux systems. Microbiol. Rev. 1996, 60, 575-608.
22. Debabov, D. Antibiotic resistance: Origins, mechanisms, approaches to counter. Appl. Biochem. Microbiol. 2013, 49, 665-671.
23. Ceri, H.; Olson, M.E.; Stremick, C.; Read, R.R.; Morck, D.; Buret, A. The calgary biofilm device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 1999, 37, 1771-1776.
24. Romero, D.; Aguilar, C.; Losick, R.; Kolter, R. Amyloid fibers provide structural integrity to Bacillus subtilis biofilms. Proc. Natl. Acad. Sci. USA 2010, 107, 2230-2234.
25. Whitchurch, C.B.; Tolker-Nielsen, T.; Ragas, P.C.; Mattick, J.S. Extracellular DNA required for bacterial biofilm formation. Science 2002, 295, 1487.
26. De la Fuente-Núñez, C.; Reffuveille, F.; Fernández, L.; Hancock, R.E.W. Bacterial biofilm development as a multicellular adaptation: Antibiotic resistance and new therapeutic strategies. Curr. Opin. Microbiol. 2013, 16, 580-589.
27. Costerton, J.W.; Lewandowski, Z.; Caldwell, D.E.; Korber, D.R.; Lappin-Scott, H.M. Microbial biofilms. Annu. Rev. Microbiol. 1995, 49, 711-745.
28. Costerton, J.W.; Stewart, P.S.; Greenberg, E.P. Bacterial biofilms: A common cause of persistent infections. Science 1999, 284, 1318-1322.
29. Khan, W.; Bernier, S.P.; Kuchma, S.L.; Hammond, J.H.; Hasan, F.; O'Toole, G.A. Aminoglycoside resistance of Pseudomonas aeruginosa biofilms modulated by extracellular polysaccharide. Int. Microbiol. 2010, 13, 207-212.
30. Yang, L.; Hu, Y.; Liu, Y.; Zhang, J.; Ulstrup, J.; Molin, S. Distinct roles of extracellular polymeric substances in Pseudomonas aeruginosa biofilm development. Environ. Microbiol. 2011, 13, 1705-1717.
31. Mulcahy, H.; Charron-Mazenod, L.; Lewenza, S. Extracellular DNA chelates cations and induces antibiotic resistance in Pseudomonas aeruginosa biofilms. PLoS Pathog. 2008, 4, e1000213.
32. Chiang, W.C.; Nilsson, M.; Jensen, P.O.; Høiby, N.; Nielsen, T.E.; Givskov, M.; Tolker-Nielsen, T. Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 2013, 57, 2352-2361.
33. Nguyen, D.; Joshi-Datar, A.; Lepine, F.; Bauerle, E.; Olakanmi, O.; Beer, K.; McKay, G.; Siehnel, R.; Schafhauser, J.; Wang, Y.; et al. Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. Science 2011, 334, 982-986.
34. Sun, F.; Qu, F.; Ling, Y.; Mao, P.; Xia, P.; Chen, H.; Zhou, D. Biofilm-associated infections: Antibiotic resistance and novel therapeutic strategies. Future Microbiol. 2013, 8, 877-886.
35. Bernier, S.P.; Lebeaux, D.; DeFrancesco, A.S.; Valomon, A.; Soubigou, G.; Coppée, J.Y.; Ghigo, J.M.; Beloin, C. Starvation, together with the sos response, mediates high biofilm-specific tolerance to the fluoroquinolone ofloxacin. PLoS Genet. 2013, 9, e1003144.
36. Lewis, K. Multidrug tolerance of biofilms and persister cells. Curr. Top. Microbiol. Immunol. 2008, 322, 107-131.
37. Mulcahy, L.R.; Burns, J.L.; Lory, S.; Lewis, K. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J. Bacteriol. 2010, 192, 6191-6199.
38. Fridman, O.; Goldberg, A.; Ronin, I.; Shoresh, N.; Balaban, N.Q. Optimization of lag time underlies antibiotic tolerance in evolved bacterial populations. Nature 2014, 513, 418-421.
39. Conibear, T.C.R.; Collins, S.L.; Webb, J.S. Role of mutation in Pseudomonas aeruginosa biofilm development. PLoS One 2009, 4, e6289.
40. Blázquez, J. Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. Clin. Infect. Dis. 2003, 37, 1201-1209.
41. Macía, M.D.; Blanquer, D.; Togores, B.; Sauleda, J.; Pérez, J.L.; Oliver, A. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob. Agents Chemother. 2005, 49, 3382-3386.
42. Townsend, J.P.; Nielsen, K.M.; Fishert, D.S.; Hartl, D.L. Horizontal acquisition of divergent chromosomal DNA in bacteria: Effects of mutator phenotypes. Genetics 2003, 164, 13-21.
43. Bernard, C.S.; Giraud, C.; Spagnolo, J.; de Bentzmann, S. Biofilms: The secret story of microbial communities. In Bacterial Pathogenesis: Molecular and Cellular Mechanisms; Locht, C., Simonet, M., Eds.; Caister Academic Press: Norfolk, UK, 2012; pp. 129-168.
44. Gillings, M.R.; Holley, M.P.; Stokes, H.W. Evidence for dynamic exchange of qac gene cassettes between class 1 integrons and other integrons in freshwater biofilms. FEMS Microbiol. Lett. 2009, 296, 282-288.
45. Koenig, J.E.; Bourne, D.G.; Curtis, B.; Dlutek, M.; Stokes, H.W.; Doolittle, W.F.; Boucher, Y. Coral-mucus-associated vibrio integrons in the great barrier reef: Genomic hotspots for environmental adaptation. ISME J. 2011, 5, 962-972.
46. Taylor, N.G.H.; Verner-Jeffreys, D.W.; Baker-Austin, C. Aquatic systems: Maintaining, mixing and mobilising antimicrobial resistance? Trends Ecol. Evol. 2011, 26, 278-284.
47. Sørensen, S.J.; Bailey, M.; Hansen, L.H.; Kroer, N.; Wuertz, S. Studying plasmid horizontal transfer in situ: A critical review. Nat. Rev. Microbiol. 2005, 3, 700-710.
48. Kloesges, T.; Popa, O.; Martin, W.; Dagan, T. Networks of gene sharing among 329 proteobacterial genomes reveal differences in lateral gene transfer frequency at different phylogenetic depths. Mol. Biol. Evol. 2011, 28, 1057-1074.
49. Domingues, S.; Harms, K.; Fricke, W.F.; Johnsen, P.J.; da Silva, G.J.; Nielsen, K.M. Natural transformation facilitates transfer of transposons, integrons and gene cassettes between bacterial species. PLoS Pathog. 2012, 8, e1002837.
50. Gillings, M.R.; Stokes, H.W. Are humans increasing bacterial evolvability? Trends Ecol. Evol. 2012, 27, 346-352.
51. Gillings, M.R.; Paulsen, I.T. Microbiology of the anthropocene. Anthropocene 2014. doi:10.1016/j.ancene.2014.06.004.
52. Zhang, L.; Mah, T.F. Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. J. Bacteriol. 2008, 190, 4447-4452.
53. Lynch, S.V.; Dixon, L.; Benoit, M.R.; Brodie, E.L.; Keyhan, M.; Hu, P.; Ackerley, D.F.; Andersen, G.L.; Matin, A. Role of the rapA gene in controlling antibiotic resistance of Escherichia coli biofilms. Antimicrob. Agents Chemother. 2007, 51, 3650-3658.
54. Scheffler, R.J.; Colmer, S.; Tynan, H.; Demain, A.L.; Gullo, V.P. Antimicrobials, drug discovery, and genome mining. Appl. Microbiol. Biotechnol. 2013, 97, 969-978.
55. Wenzel, R.P. The antibiotic pipeline - Challenges, costs, and values. N. Engl. J. Med. 2004, 351, 523-526.
56. Katz, M.L.; Mueller, L.V.; Polyakov, M.; Weinstock, S.F. Where have all the antibiotic patents gone? Nat. Biotechnol. 2006, 24, 1529-1531.
57. Hancock, R.E.W. The end of an era? Nat. Rev. Drug Discov. 2007, 6, 28.
58. Projan, S.J. Whither antibacterial drug discovery? Drug Discov. Today 2008, 13, 279-280.
59. Egan, S.; Penesyan, A. Marine bacteria as a source of new antibiotics. In Bioactive Compounds: Types, Biological Activities and Health Effects; Nova Science Publishers: Hauppauge, NY, USA, 2012; pp. 381-412.
60. Payne, D.J.; Gwynn, M.N.; Holmes, D.J.; Pompliano, D.L. Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 2007, 6, 29-40.
61. Larsen, T.O.; Smedsgaard, J.; Nielsen, K.F.; Hansen, M.E.; Frisvad, J.C. Phenotypic taxonomy and metabolite profiling in microbial drug discovery. Nat. Prod. Rep. 2005, 22, 672-695.
62. Larsson, J.; Gottfries, J.; Muresan, S.; Backlund, A. Chemgps-np: Tuned for navigation in biologically relevant chemical space. J. Nat. Prod. 2007, 70, 789-794.
63. Jose, P.A.; Jebakumar, S.R.D. Unexplored hypersaline habitats are sources of novel actinomycetes. Front. Microbiol. 2014, 5, 242.
64. Penesyan, A.; Kjelleberg, S.; Egan, S. Development of novel drugs from marine surface associated microorganisms. Mar. Drugs 2010, 8, 438-459.
65. Penesyan, A.; Marshall-Jones, Z.; Holmstrom, C.; Kjelleberg, S.; Egan, S. Antimicrobial activity observed among cultured marine epiphytic bacteria reflects their potential as a source of new drugs. FEMS Microbiol. Ecol. 2009, 69, 113-124.
66. Blunt, J.W.; Copp, B.R.; Keyzers, R.A.; Munro, M.H.G.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2014, 31, 160-258.
67. Blunt, J.W.; Copp, B.R.; Keyzers, R.A.; Munro, M.H.G.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2013, 30, 237-323.
68. Bérdy, J. Bioactive microbial metabolites: A personal view. J. Antibiot. (Tokyo) 2005, 58, 1-26.
69. Handelsman, J. Metagenomics: Application of genomics to uncultured microorganisms. Microbiol. Mol. Biol. Rev. 2004, 68, 669-685.
70. Penesyan, A.; Ballestriero, F.; Daim, M.; Kjelleberg, S.; Thomas, T.; Egan, S. Assessing the effectiveness of functional genetic screens for the identification of bioactive metabolites. Mar. Drugs 2013, 11, 40-49.
71. Ling, L.L.; Schneider, T.; Peoples, A.J.; Spoering, A.L.; Engels, I.; Conlon, B.P.; Mueller, A.; Schaberle, T.F.; Hughes, D.E.; Epstein, S.; et al. A new antibiotic kills pathogens without detectable resistance. Nature 2015, 517, 455-459.
72. Wong, F.T.; Khosla, C. Combinatorial biosynthesis of polyketides-a perspective. Curr. Opin. Chem. Biol. 2012, 16, 117-123.
73. Floss, H.G. Combinatorial biosynthesis-potential and problems. J. Biotechnol. 2006, 124, 242-257.
74. Tsoi, C.J.; Khosla, C. Combinatorial biosynthesis of "unnatural" natural products: The polyketide example. Chem. Biol. 1995, 2, 355-362.
75. Cane, D.E. Programming of erythromycin biosynthesis by a modular polyketide synthase. J. Biol. Chem. 2010, 285, 27517-27523.
76. Fisch, K.M.; Bakeer, W.; Yakasai, A.A.; Song, Z.; Pedrick, J.; Wasil, Z.; Bailey, A.M.; Lazarus, C.M.; Simpson, T.J.; Cox, R.J. Rational domain swaps decipher programming in fungal highly reducing polyketide synthases and resurrect an extinct metabolite. J. Am. Chem. Soc. 2011, 133, 16635-16641.
77. Livermore, D.M. The need for new antibiotics. Clin. Microbiol. Infec. Suppl. 2004, 10, 1-9.
78. Koehn, F.E.; Carter, G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 2005, 4, 206-220.
79. Spellberg, B.; Guidos, R.; Gilbert, D.; Bradley, J.; Boucher, H.W.; Scheld, W.M.; Bartlett, J.G.; Edwards, J.; America, T.I.D.S.O. The epidemic of antibiotic-resistant infections: A call to action for the medical community from the infectious diseases society of america. Clin. Infect. Dis. 2008, 46, 155-164.
80. McDougald, D.; Rice, S.A.; Barraud, N.; Steinberg, P.D.; Kjelleberg, S. Should we stay or should we go: Mechanisms and ecological consequences for biofilm dispersal. Nat. Rev. Microbiol. 2012, 10, 39-50.
81. Kolodkin-Gal, I.; Romero, D.; Cao, S.; Clardy, J.; Kolter, R.; Losick, R. D-amino acids trigger biofilm disassembly. Science 2010, 328, 627-629.
82. Hochbaum, A.I.; Kolodkin-Gal, I.; Foulston, L.; Kolter, R.; Aizenberg, J.; Losick, R. Inhibitory effects of D-amino acids on Staphylococcus aureus biofilm development. J. Bacteriol. 2011, 193, 5616-5622.
83. Barraud, N.; Hassett, D.J.; Hwang, S.H.; Rice, S.A.; Kjelleberg, S.; Webb, J.S. Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J. Bacteriol. 2006, 188, 7344-7353.
84. Barraud, N.; Schleheck, D.; Klebensberger, J.; Webb, J.S.; Hassett, D.J.; Rice, S.A.; Kjelleberg, S. Nitric oxide signaling in Pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic di-GMP levels, and enhanced dispersal. J. Bacteriol. 2009, 191, 7333-7342.
85. Overhage, J.; Campisano, A.; Bains, M.; Torfs, E.C.W.; Rehm, B.H.A.; Hancock, R.E.W. Human host defense peptide ll-37 prevents bacterial biofilm formation. Infect. Immun. 2008, 76, 4176-4182.
86. De La Fuente-Núñez, C.; Korolik, V.; Bains, M.; Nguyen, U.; Breidenstein, E.B.M.; Horsman, S.; Lewenza, S.; Burrows, L.; Hancock, R.E.W. Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimicrob. Agents Chemother. 2012, 56, 2696-2704.
87. Manefield, M.; de Nys, R.; Kumar, N.; Read, R.; Givskov, M.; Steinberg, P.; Kjelleberg, S. Evidence that halogenated furanones from Delisea pulchra inhibit acylated homoserine lactone (AHL)-mediated gene expression by displacing the AHL signal from its receptor protein. Microbiology 1999, 145, 283-291.
88. Manefield, M.; Kjelleberg, S.; Givskov, M. Controlling bacterial infection by inhibiting intercellular signalling. Curr. Med. Chem.: Anti-Infect. Agents 2003, 2, 213-218.
89. Bjarnsholt, T.; Givskov, M. Quorum sensing inhibitory drugs as next generation antimicrobials: Worth the effort? Curr. Infect. Dis. Rep. 2008, 10, 22-28.